Komori
Other Disclosures4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Patent Grant Decision for DFP-10917’s Long-Term Stable Formulation

A new formulation technology enabling long-term storage of DFP-10917 received a decision to grant a patent. Long-term stability of more than 5 years was also confirmed at industrial scale, improving formulation-related challenges toward commercialization.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
5
More than years of long-term stability
Wording
Conditional
How definitive the wording is.

Announced details

DFP-10917Combination therapy of DFP-10917 and venetoclax
Applicable field (uses covered by this announcement)

Long-term storage of anticancer drugs, continued administration, commercialization, and a Phase 3 clinical trial for combination therapy with DFP-10917 and Venetoclax

What the company reported numerically
Quantitative Effects

The conventional formulation had stability of approximately 3 months at around room temperature. The new formulation’s long-term stability of more than 5 years was confirmed at industrial scale.

Relationship between the counterparty and the company
Delta-Fly Pharma,Inc.4598
Relationship with the Company

The Company developed the formulation technology for DFP-10917, filed an international application with WIPO, and had it published internationally. Going forward, the Company plans to discuss with the FDA a request for conditional NDA approval and the transition to a Phase 3 clinical trial.

CounterpartyWorld Intellectual Property Organization (WIPO)U.S. Food and Drug Administration (FDA)

The International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the body responsible for international publication. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority for pharmaceuticals. Other details: Not disclosed.

Registration number and expiry date

An international application was filed under the Patent Cooperation Treaty (PCT) and published internationally by WIPO’s International Bureau (IB). Registration number and validity period: Not disclosed.

Location (as indicated in this announcement)

Industrial scale

Impact on Business Performance

The Company says it will use the formulation technology under the present invention in the development and commercialization of DFP-10917 and link this to future business expansion, but the specific amount of the impact on financial results is Not disclosed.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

World Intellectual Property Organization (WIPO)

Announced details
ItemDetails
Names of Products / Services CoveredDFP-10917, Combination therapy of DFP-10917 and venetoclax
CounterpartyWorld Intellectual Property Organization (WIPO), U.S. Food and Drug Administration (FDA)
Counterparty overviewThe International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the body responsible for international publication. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority for pharmaceuticals. Other details: Not disclosed.
Relationship with the CompanyThe Company developed the formulation technology for DFP-10917, filed an international application with WIPO, and had it published internationally. Going forward, the Company plans to discuss with the FDA a request for conditional NDA approval and the transition to a Phase 3 clinical trial.
Applicable areaLong-term storage of anticancer drugs, continued administration, commercialization, and a Phase 3 clinical trial for combination therapy with DFP-10917 and Venetoclax
Registration number and expiry dateAn international application was filed under the Patent Cooperation Treaty (PCT) and published internationally by WIPO’s International Bureau (IB). Registration number and validity period: Not disclosed.
Location scaleIndustrial scale
Quantitative EffectsThe conventional formulation had stability of approximately 3 months at around room temperature. The new formulation’s long-term stability of more than 5 years was confirmed at industrial scale.
Impact on Business PerformanceThe Company says it will use the formulation technology under the present invention in the development and commercialization of DFP-10917 and link this to future business expansion, but the specific amount of the impact on financial results is Not disclosed.
SourceWorld Intellectual Property Organization (WIPO)
Items this document does not state (8)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The conventional lyophilized formulation had stability of only approximately 3 months at around room temperature, creating challenges for commercialization intended for long-term storage and continued administration. The new technology promotes the growth of Type II microcrystals in DFP-10917, achieving long-term stability.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Patent Grant Decision for DFP-10917’s Long-Term Stable Formulation | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori